Simoa® NF-light™: Ultrasensitive Blood-Based Biomarker Detection for Identification of Neuropathology
App Note
Survivors of cardiac arrest and prolonged open-heart surgery have increased risks of developing adverse neurological outcomes in the long term1,2. Identifying high-risk patients at an early stage allows clinicians to propose better therapeutic strategies, resulting in significant improvements in patient management and quality of life. Download our app note to learn how detection of NfL with Simoa® can support the identification of neuropathology and could help improve therapeutic management.
1. Perkins GD, Callaway CW, Haywood K, et al. Brain injury after cardiac arrest. The Lancet. 2021;398(10307):1269-1278. doi:10.1016/s0140-6736(21)00953-3
2. Raffa GM, Agnello F, Occhipinti G, et al. Neurological complications after cardiac surgery: a retrospective case-control study of risk factors and outcome. Journal of Cardiothoracic Surgery. 2019;14(1)doi:10.1186/s13019-019-0844-8